Clinical Trials Logo

Clinical Trial Summary

The purpose of this phase II study is to evaluate the outcomes of patients treated with an investigational radiation regimen using stereotactic radiotherapy for oligometastatic prostate cancer and to establish efficacy (producing a desired result or effect) and safety in this setting.


Clinical Trial Description

This study will serve as a component of a larger program investigating the benefits of stereotactic radiotherapy in patients with metastatic disease. This particular study will serve as a benchmark analysis. All patients will receive stereotactic radiotherapy directed at metastatic tumors. If primary prostate cancer is active and has not previously been treated with radiation therapy, conventional radiation therapy (6-8 weeks of daily treatment) may be recommended. The metastatic tumor will be treated at the same time. Hormone therapy will be recommended for all patients. Patients will be asked to complete questionnaires at regular intervals. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01859221
Study type Interventional
Source University of Florida
Contact
Status Completed
Phase N/A
Start date May 2013
Completion date September 13, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT03940235 - Radioablation With or Without Androgen DeprIvation Therapy in Metachronous Prostate Cancer OligometaStAsis Phase 2
Recruiting NCT06060652 - Prostate Oligometastatic Cancer Management Driven by Disease Biology et/or Immunoactivity (PROMETEO)
Recruiting NCT04610372 - 5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT) N/A
Recruiting NCT05915442 - Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer Phase 2
Active, not recruiting NCT04992026 - The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer Phase 2
Recruiting NCT05560659 - Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy Phase 2
Completed NCT02192788 - Phase II Study of SBRT as Treatment for Oligometastases in Prostate Cancer N/A
Recruiting NCT06387056 - Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) Phase 2